Draganfly Reports Revenue Growth Amid Persistent Financial and Operational Concerns

What happened

Draganfly announced record Q4 and full-year revenue for fiscal 2025, with Q4 revenue up 18.5% year-over-year and annual revenue increasing 17.8%. However, the DeepValue report reveals that the company remains deeply unprofitable, with negative free cash flow and a gross margin of only 19.5% in Q3'25. Critical issues persist, including a reliance on repeated equity financing—such as a recent $50M offering—and a lack of disclosed contract values or repeat orders for key defense wins. This revenue growth, while superficially positive, does not address underlying weaknesses in operational leverage or the conversion of defense headlines into sustainable, scalable revenue. Investors must therefore view this news skeptically, as the core business model still depends on external capital rather than self-funding growth.

Implication

The revenue increase suggests some demand traction, but it is insufficient to offset persistent losses and cash burn, which continue to erode shareholder value. Without disclosed volumes or monetary terms for defense contracts, the growth narrative lacks substance and may not translate to sustainable earnings or operating leverage. The company's history of discounted equity raises, including a recent $50M offering, reinforces dilution risks and limits upside potential until financing cadence slows. Investors should focus on upcoming SEC filings for proof of repeat orders, gross margin stabilization above 20%, and any new equity issuance that could further compress per-share value. Until these metrics show material improvement, DPRO's stock is likely to remain volatile with limited compounding potential, aligning with the 'WAIT' rating.

Thesis delta

The reported revenue growth does not shift the investment thesis, as it fails to address the core concerns outlined in the DeepValue report. The thesis remains that DPRO needs disclosed repeat defense orders with volumes and pricing, along with reduced dilution after the $50M raise, to justify a higher rating. This news reinforces the 'WAIT' stance, as it highlights top-line progress but ignores critical profitability and funding issues.